Jazz Pharmaceuticals (JAZZ) Earnings Date & Reports

Key Takeaways

• Jazz Pharmaceuticals reports third-quarter 2026 results on Monday, November 2, 2026, after the U.S. market close.
• Consensus estimates point to revenue of roughly $1.20 billion, while adjusted earnings per share (EPS) forecasts span a wide range of about $5.35 to $6.69 depending on the data provider.
• Investors will focus on the early launch of Ziihera (zanidatamab-hrii) in first-line HER2-positive gastroesophageal adenocarcinoma, which received U.S. Food and Drug Administration (FDA) approval in August 2026.
• Xywav and Epidiolex remain core growth engines after generating $471 million and $292 million in second-quarter net product sales, respectively.
• Management raised full-year 2026 revenue guidance to $4.60–$4.75 billion after strong first-half results, raising expectations for the third-quarter update.

Earnings Context and Why It Matters

Jazz Pharmaceuticals enters its third-quarter report with considerable momentum. The company posted record quarterly revenue of $1.21 billion in the second quarter, up 16% year over year, and lifted its full-year 2026 revenue outlook to $4.60–$4.75 billion. The November report is the first full-quarter look at the commercial launch of Ziihera in a new, larger first-line cancer indication, making it a key test of the company's oncology growth story. At the same time, investors will be watching whether the sleep and epilepsy franchises sustain their double-digit growth despite generic competition and emerging rivals. The results will help clarify whether Jazz's diversified portfolio can keep delivering against a backdrop of rising R&D spending and periodic one-time charges.

Earnings Expectations

Wall Street expects Jazz Pharmaceuticals to report revenue of approximately $1.20 billion for the third quarter of 2026, a modest sequential step down from the record $1.21 billion recorded in the second quarter. Adjusted EPS forecasts are unusually dispersed, ranging from about $5.35 (Zacks Research) to $6.69 (MarketBeat), reflecting uncertainty around research-and-development items and one-time expenses that can swing quarterly earnings.

For context, in the second quarter Jazz delivered non-GAAP adjusted EPS of $5.71, missing the $6.18 consensus estimate largely because of $77 million in acquired in-process research and development (IPR&D) expenses, which reduced adjusted EPS by 94 cents. Revenue, however, beat expectations. Investors will be watching closely for a similar dynamic this quarter, as the underlying commercial business has consistently outperformed even when headline EPS has been pressured by one-time items.

Beyond the headline numbers, the market will track Xywav patient additions, Epidiolex demand, and early Ziihera sales in its newly approved first-line setting. Management's updated full-year guidance and any commentary on the second interim overall survival analysis from the HERIZON-GEA-01 trial will also be closely scrutinized.

AI Screener

For investors looking to monitor earnings season efficiently, Tickeron's AI Screener offers an AI-powered stock and ETF discovery tool that helps traders filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. As earnings season unfolds, tools like this can help investors surface relevant names across sectors in a fraction of the time.

Market Reaction and Investor Sentiment

Jazz Pharmaceuticals shares have climbed sharply in 2026, rising roughly 48% year to date through early August, driven by strong commercial execution and the FDA approval of Ziihera in first-line HER2-positive gastroesophageal adenocarcinoma. Sentiment heading into the third-quarter report is broadly constructive, with most analysts maintaining Buy or equivalent ratings and an average price target near $279 as of late August.

Still, several risk factors cloud the setup. The stock has historically moved meaningfully around earnings, with an average post-earnings move of about 4.6%. A disappointing EPS print, as seen last quarter, could renew concerns about IPR&D volatility, while weaker-than-expected Xywav patient growth or a slow Ziihera ramp would test the growth narrative. Conversely, a clean revenue beat paired with upbeat launch commentary would likely reinforce the bullish case.

Forward Outlook and Key Factors to Monitor

The most important near-term catalyst is the commercial trajectory of Ziihera (zanidatamab-hrii) in first-line HER2-positive gastroesophageal adenocarcinoma, approved in August 2026. Investors will be looking for early launch metrics, reimbursement uptake, and any signal on how quickly the product can expand beyond its original biliary tract cancer indication.

A second item to watch is the durability of the sleep franchise. Xywav added roughly 525 net patients in the second quarter, reaching about 17,125 active patients, and management now expects double-digit full-year growth. However, high-sodium oxybate generics and emerging competitors such as Lumryz and orexin-based therapies could pressure that momentum over time.

In oncology, Jazz plans to remove Zepzelca's second-line small cell lung cancer indication following the LAGOON trial, which may accelerate erosion of that revenue stream even as first-line maintenance use grows. The Modeyso (dordaviprone) launch remains an early-stage growth story, with a key overall survival interim analysis from the Phase 3 ACTION trial now expected in the first half of 2027.

Finally, investors should monitor margin and expense trends. Non-GAAP adjusted gross margin slipped modestly year over year in the second quarter because of third-party royalties on Zepzelca and Modeyso, and R&D spending continues to rise as the pipeline advances. Guidance revisions, tax-rate assumptions, and any new business development activity will also shape the outlook following the report.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations